SCHEMBL1616240

SCHEMBL1616240

COC(=O)c1ccc(CNC(=O)C(=O)Nc2ccc3c(c2)C(C)(C)CCC3(C)C)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP26A1 O43174 6/20 0.55
CYP26B1 Q9NR63 2/20 0.55
CYP3A4 P08684 5/20 0.53
KMT2A Q03164 6/20 0.51
RARA P10276 4/20 0.51
RARB P10826 4/20 0.51
RARG P13631 4/20 0.51
MEN1 O00255 3/20 0.51
PGR P06401 1/20 0.51
ADORA3 P0DMS8 1/20 0.51
TBXA2R P21731 1/20 0.51
BLVRB P30043 1/20 0.51
ALDH1A1 P00352 3/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
MAPT P10636 1/20 0.47
MAPK1 P28482 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
TSHR P16473 1/20 0.46
CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1615594 0.88 CYP26A1 (0.60) CYP26A1CYP26B1CYP3A4KMT2ARARA
SCHEMBL1616029 0.87 CYP26A1 (0.60) CYP26A1CYP26B1CYP3A4KMT2ARARA
SCHEMBL8677671 0.85 CYP3A4 (0.61) CYP26A1CYP26B1CYP3A4KMT2ARARA
SCHEMBL8839355 0.82 CYP3A4 (0.61) CYP26A1CYP26B1CYP3A4KMT2ARARA
SCHEMBL1615896 0.81 CYP26A1 (0.76) CYP26A1CYP26B1CYP3A4KMT2ARARA
SCHEMBL6027259 0.81 HIF1A (0.46) CYP26A1CYP26B1CYP3A4KMT2ARARA
SCHEMBL17049087 0.78 CYP3A4 (0.61) CYP26A1CYP26B1CYP3A4KMT2ARARA
SCHEMBL8839191 0.77 CYP3A4 (0.57) CYP26A1CYP26B1CYP3A4KMT2ARARA
SCHEMBL1616205 0.76 CYP3A4 (0.51) CYP26A1CYP26B1CYP3A4KMT2ARARA
SCHEMBL1615390 0.76 RARA (0.76) CYP26A1CYP26B1CYP3A4KMT2ARARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7923579-B2 Tricyclic hydroxamate and benzamide derivatives, compositions and methods EXONHIT THERAPEUTICS S.A. (FR) 2011-04-12 US disclosed
US-7923579-B2 Tricyclic hydroxamate and benzamide derivatives, compositions and methods EXONHIT THERAPEUTICS S.A. (FR) 2011-04-12 US disclosed
US-7923579-B2 Tricyclic hydroxamate and benzamide derivatives, compositions and methods EXONHIT THERAPEUTICS S.A. (FR) 2011-04-12 US disclosed
EP-1692097-B1 TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS EXONHIT THERAPEUTICS SA (FR) 2009-09-02 EP disclosed
EP-1692097-B1 TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS EXONHIT THERAPEUTICS SA (FR) 2009-09-02 EP disclosed
US-20070129368-A1 Tricyclic hydroxamate and benzamide derivatives, compositions and methods EXONHIT THERAPEUTICS S.A. (FR) 2007-06-07 US disclosed
US-20070129368-A1 Tricyclic hydroxamate and benzamide derivatives, compositions and methods EXONHIT THERAPEUTICS S.A. (FR) 2007-06-07 US disclosed
US-20070129368-A1 Tricyclic hydroxamate and benzamide derivatives, compositions and methods EXONHIT THERAPEUTICS S.A. (FR) 2007-06-07 US disclosed
EP-1692097-A1 TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS Exonhit Therapeutics SA (FR) 2006-08-23 EP disclosed
WO-2005058803-A1 TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS EXONHIT THERAPEUTICS SA (FR) 2005-06-30 WO disclosed
WO-2005058803-A1 TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS EXONHIT THERAPEUTICS SA (FR) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129368-A1 Tricyclic hydroxamate and benzamide derivatives, compositions and methods HDAC5, HDAC1, HDAC2 CYP26A1 1813/4885CYP26B1 1989/4885CYP3A4 1996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.